JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.
Skip to content
Study at a glance
AI-extracted from the abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Provided herein are novel 6,5-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse, and headaches, and processes for preparing such compounds.
Create a free account to bookmark articles, vote on relevance, generate your own syntheses, and join the discussion.
Related reading
Novel 5,6-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches
ACS Medicinal Chemistry Letters
June 3, 2026
Novel Serotonergic Psychedelic Agents as 5-HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders
ACS Medicinal Chemistry Letters
August 25, 2025
Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders.
ACS Med Chem Lett
March 13, 2025
Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders
ACS Medicinal Chemistry Letters
October 22, 2025
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.
ACS Med Chem Lett
February 11, 2025
© 2026 The Consciousness Library
Support Our Mission
Choose your preferred way to support The Consciousness Library's work in advancing consciousness research.
A registered 501(c)(3) nonprofit; donations are tax-deductible in the US.
Donations are processed by Mindscape Collective, our legal entity, and may appear that way on your statement.